- Home
- Publications
- Publication Search
- Publication Details
Title
Antibodies to watch in 2023
Authors
Keywords
-
Journal
mAbs
Volume 15, Issue 1, Pages -
Publisher
Informa UK Limited
Online
2022-12-06
DOI
10.1080/19420862.2022.2153410
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
- (2022) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- (2022) Jeffrey S Heier et al. LANCET
- Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
- (2022) Charles C Wykoff et al. LANCET
- Antibodies to watch in 2022
- (2022) Hélène Kaplon et al. mAbs
- Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
- (2022) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation–Associated Thrombotic Microangiopathy
- (2022) Samer K. Khaled et al. JOURNAL OF CLINICAL ONCOLOGY
- Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
- (2022) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2022) Jie Wang et al. LANCET ONCOLOGY
- Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants
- (2022) Laura L. Hammitt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity
- (2022) Joseph Domachowske et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of ormutivimab, a novel recombinant human anti-rabies monoclonal antibody, in post-exposure prophylaxis animal models
- (2022) Li-li zhai et al. Travel Medicine and Infectious Disease
- Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
- (2022) Rajat Bannerji et al. Lancet Haematology
- Sutimlimab in patients with cold agglutinin disease: Results of the randomized placebo-controlled phase 3 CADENZA trial
- (2022) Alexander Röth et al. BLOOD
- Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
- (2022) Yuankai Shi et al. HEMATOLOGICAL ONCOLOGY
- GEMSTONE-201: Preplanned primary analysis of a multicenter, single-arm, phase 2 study of sugemalimab (suge) in patients (pts) with relapsed or refractory extranodal natural killer/T cell lymphoma (R/R ENKTL).
- (2022) Huiqiang Huang et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of the anti–PD-L1 monoclonal antibody socazolimab for recurrent or metastatic cervical cancer: Results from the phase I dose-escalation and expansion study.
- (2022) Jusheng An et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated efficacy and safety results from a phase 1b study of the PD-1 antagonist CS1003 combined with lenvatinib (LEN) as first-line (1L) treatment in Chinese patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2022) Lin Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Teclistamab in Relapsed or Refractory Multiple Myeloma
- (2022) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II / III results of the anti‐TNF multivalent NANOBODY ® compound ‘ozoralizumab’ in patient with rheumatoid arthritis ( OHZORA trial)
- (2022) Tsutomu Takeuchi et al. Arthritis & Rheumatology
- Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial
- (2022) Hugh Montgomery et al. Lancet Respiratory Medicine
- Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events
- (2022) Zhaoliang Huang et al. Frontiers in Immunology
- Safety, tolerability, and pharmacokinetics/pharmacodynamics of JMT103 in patients with bone metastases from solid tumors
- (2022) Xu Liang et al. Frontiers in Oncology
- Population Pharmacodynamic Analyses of Human Anti-Rabies Virus Monoclonal Antibody (Ormutivimab) in Healthy Adult Subjects
- (2022) Junnan Zhang et al. Vaccines
- HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
- (2022) Josep Tabernero et al. Future Oncology
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
- (2022) Ying Cheng et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names
- (2022) Ian Wilkinson et al. mAbs
- The On- and Off-Ramps of Oncology Accelerated Approval
- (2022) Lola A. Fashoyin-Aje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
- (2022) Lawrence Steinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes
- (2022) Sergey Shcherbinin et al. JAMA Neurology
- POD1UM-303/InterAACT 2: A phase III, global, randomized, double-blind study of retifanlimab or placebo plus carboplatin–paclitaxel in patients with locally advanced or metastatic squamous cell anal carcinoma
- (2022) Sheela Rao et al. Frontiers in Oncology
- Antibodies to watch in 2021
- (2021) Hélène Kaplon et al. mAbs
- Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
- (2021) Jie Wang et al. JAMA Oncology
- Efficacy and safety of JMT103 in patients with giant cell tumor of bone: A multicenter, single-arm, open-label, phase Ib/II study.
- (2021) Xiaohui Niu et al. JOURNAL OF CLINICAL ONCOLOGY
- Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
- (2021) Shun Lu et al. Journal of Thoracic Oncology
- Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
- (2021) Martin Hutchings et al. LANCET
- Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
- (2021) Hai-Qiang Mai et al. NATURE MEDICINE
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II randomized, double-blind, placebo-controlled study
- (2021) Jing Li et al. RHEUMATOLOGY
- Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies
- (2021) K. Kabashima et al. BRITISH JOURNAL OF DERMATOLOGY
- A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab
- (2021) Andrew McKenzie et al. CTS-Clinical and Translational Science
- Trial of Spesolimab for Generalized Pustular Psoriasis
- (2021) Hervé Bachelez et al. NEW ENGLAND JOURNAL OF MEDICINE
- HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
- (2020) Jibin Zhang et al. mAbs
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Antibodies to watch in 2018
- (2018) Hélène Kaplon et al. mAbs
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody
- (2018) Zenjiro Sampei et al. PLoS One
- Antibodies to watch in 2017
- (2016) Janice M. Reichert mAbs
- Antibodies to watch in 2016
- (2015) Janice M. Reichert mAbs
- Antibodies to watch in 2015
- (2014) Janice M Reichert mAbs
- Antibodies to watch in 2014
- (2013) Janice M Reichert mAbs
- Which are the antibodies to watch in 2013?
- (2013) Janice M. Reichert mAbs
- Which are the antibodies to watch in 2012?
- (2012) Janice M. Reichert mAbs
- Antibody-based therapeutics to watch in 2011
- (2011) Janice M. Reichert mAbs
- Antibodies to watch in 2010
- (2010) Janice M. Reichert mAbs
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search